ALEXANDER KEITH STEWART

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint How I treat multiple myeloma in younger patients
    A Keith Stewart
    Mayo Clinic Arizona, Scottsdale, Boston, MA, USA
    Blood 114:5436-43. 2009
  2. ncbi request reprint Analysis of PTEN deletions and mutations in multiple myeloma
    Hong Chang
    Department of Laboratory Hematology, Princess Margaret Hospital University Health Network, University of Toronto, Ont, Canada M5G 2M9
    Leuk Res 30:262-5. 2006
  3. ncbi request reprint Prognostic and therapeutic significance of myeloma genetics and gene expression profiling
    A Keith Stewart
    Hematology Oncology, Room 3 008, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    J Clin Oncol 23:6339-44. 2005
  4. ncbi request reprint Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
    W Wei Lynn Wong
    Departments of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Mol Cancer Ther 6:1886-97. 2007
  5. doi request reprint Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements
    Jan B Egan
    Comprehensive Cancer Center, Mayo Clinic, Scottsdale, Arizona, United States of America
    PLoS ONE 9:e87113. 2014
  6. pmc A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
    A Keith Stewart
    Division of Hematology Oncology, Mayo Clinic in Arizona, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA
    Blood 121:1517-23. 2013
  7. doi request reprint Novel therapeutics in multiple myeloma
    A Keith Stewart
    Division of Hematology Oncology, Mayo Clinic in Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, USA
    Hematology 17:S105-8. 2012
  8. ncbi request reprint A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
    A K Stewart
    Department of Medicine, Division of Hematology Oncology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Leukemia 21:529-34. 2007
  9. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
  10. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010

Research Grants

  1. A Genome Wide RNAi Vulnerability Map for Myeloma
    ALEXANDER KEITH STEWART; Fiscal Year: 2010
  2. The Molecular Basis for Bortezomib Activity
    Alexander Stewart; Fiscal Year: 2007
  3. The Molecular Basis for Bortezomib Activity
    Alexander Stewart; Fiscal Year: 2009
  4. The Molecular Basis for Bortezomib Activity
    ALEXANDER KEITH STEWART; Fiscal Year: 2010

Detail Information

Publications54

  1. doi request reprint How I treat multiple myeloma in younger patients
    A Keith Stewart
    Mayo Clinic Arizona, Scottsdale, Boston, MA, USA
    Blood 114:5436-43. 2009
    ..When access to newer drugs is restricted participation in clinical trials should be pursued...
  2. ncbi request reprint Analysis of PTEN deletions and mutations in multiple myeloma
    Hong Chang
    Department of Laboratory Hematology, Princess Margaret Hospital University Health Network, University of Toronto, Ont, Canada M5G 2M9
    Leuk Res 30:262-5. 2006
    ..Our results indicate that alterations of PTEN are uncommon in MM patients, and PTEN deletions tend to occur in advanced disease suggesting that they are secondary, rather than primary, events in the pathogenesis of MM...
  3. ncbi request reprint Prognostic and therapeutic significance of myeloma genetics and gene expression profiling
    A Keith Stewart
    Hematology Oncology, Room 3 008, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    J Clin Oncol 23:6339-44. 2005
    ..Importantly, we recommend that all clinical trials now adopt routine genetic testing and risk stratification...
  4. ncbi request reprint Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
    W Wei Lynn Wong
    Departments of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Mol Cancer Ther 6:1886-97. 2007
    ..003). These results suggest that statins may be a useful molecular targeted therapy in the treatment of a subset of MM...
  5. doi request reprint Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements
    Jan B Egan
    Comprehensive Cancer Center, Mayo Clinic, Scottsdale, Arizona, United States of America
    PLoS ONE 9:e87113. 2014
    ..In conclusion, this work is the first to report the entire genome of a well-differentiated liposarcoma with novel chromosomal rearrangements associated with amplification of therapeutically targetable genes such as MDM2 and DDR2. ..
  6. pmc A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
    A Keith Stewart
    Division of Hematology Oncology, Mayo Clinic in Arizona, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA
    Blood 121:1517-23. 2013
    ....
  7. doi request reprint Novel therapeutics in multiple myeloma
    A Keith Stewart
    Division of Hematology Oncology, Mayo Clinic in Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, USA
    Hematology 17:S105-8. 2012
    ..Other small molecules or monoclonal antibodies with novel targets such as kinase inhibitors(AKT, CDK5) and cell surface receptors (e.g. elotuzumab) are undergoing active investigation...
  8. ncbi request reprint A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
    A K Stewart
    Department of Medicine, Division of Hematology Oncology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Leukemia 21:529-34. 2007
    ..Conversely, the 75% of patients remaining have more favorable outcomes using existing - albeit non-curative - therapeutic options...
  9. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  10. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  11. doi request reprint Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  12. pmc Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Cancer Cell 12:131-44. 2007
    ..These results highlight the critical importance of the NF-kappaB pathway in the pathogenesis of multiple myeloma...
  13. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  14. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  15. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  16. ncbi request reprint Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach
    Rafael Fonseca
    Mayo Clinic, 13208 East Shea Boulevard, Collaborative Research Building 3 006, Scottsdale, AZ 85259 5494, USA
    Mol Cancer Ther 6:802-10. 2007
    ....
  17. pmc AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
    Marta Chesi
    Comprehensive Cancer Center, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Cancer Cell 13:167-80. 2008
    ....
  18. pmc Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity
    Rodger E Tiedemann
    Mayo Clinic, Comprehensive Cancer Center, Division of Hematology and Oncology, Scottsdale, Arizona, USA
    J Clin Invest 118:1750-64. 2008
    ..These data support targeted repression of cyclin D genes as a therapeutic strategy for human malignancies...
  19. doi request reprint High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
    Joseph R Mikhael
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Br J Haematol 144:169-75. 2009
    ..Neuropathy (any grade) was seen in 25% of the patients and led to discontinuation in 5%. Bortezomib, alone and combined with dexamethasone, is safe and effective in heavily pretreated patients with relapsed or refractory MM...
  20. doi request reprint Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo
    Rodger E Tiedemann
    Division of Hematology and Oncology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ 85259, USA
    Blood 113:4027-37. 2009
    ....
  21. pmc Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
    Rodger E Tiedemann
    Division of Hematology Oncology, Mayo Clinic Arizona, 13400 Shea Blvd, Scottsdale, AZ 85259, USA
    Blood 115:1594-604. 2010
    ..As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma...
  22. doi request reprint Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 27:5008-14. 2009
    ..We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma...
  23. ncbi request reprint Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1047-53. 2006
    ..These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits...
  24. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
    ..To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma...
  25. ncbi request reprint Genetics and cytogenetics of multiple myeloma: a workshop report
    Rafael Fonseca
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 64:1546-58. 2004
    ..Areas in need of further study were identified. The study of the genetic aberrations will likely form the platform for targeted therapy for the disease...
  26. pmc Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia
    Esteban Braggio
    Mayo Clinic, Scottsdale, Arizona 85259 5494, USA
    Cancer Res 69:3579-88. 2009
    ....
  27. ncbi request reprint Review of molecular diagnostics in multiple myeloma
    A Keith Stewart
    Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Expert Rev Mol Diagn 7:453-9. 2007
    ..This classification will identify multiple myeloma patients at high genetic risk for early progression after conventional therapies...
  28. doi request reprint Acute lung toxicity related to pomalidomide
    Holly L Geyer
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Chest 140:529-33. 2011
    ..We conclude that pulmonary toxicity is a potential adverse effect of pomalidomide therapy and encourage physicians to remain cognizant of its clinical presentation...
  29. ncbi request reprint p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
    Hong Chang
    Department of Laboratory Hematology, Princess Margaret Hospital University Health Network, Toronto, ON, Canada
    Blood 105:358-60. 2005
    ..0009) or overall survival (P = .0002) in patients with MM after high-dose chemotherapy and autologous stem cell transplantation...
  30. ncbi request reprint Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis
    Hong Chang
    Department of Laboratory Hematology, Princess Margaret Hospital, Toronto, Canada
    Leuk Lymphoma 45:965-9. 2004
    ..Since 13q deletions, IgH translocations and a hypodiploid karyotype are significant prognostic factors for MM, our study illustrates the importance of combining conventional cytogenetics with interphase FISH analysis in patients with MM...
  31. ncbi request reprint RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to bcl-xL-expressing myeloma cells in vitro and in vivo
    Jonathan B Pollett
    Division of Experimental Therapeutics, Toronto General Research Institute, and Department of Medical Oncology, Princess Margaret Hospital, M5G 2M9, Toronto, Ontario, Canada
    Mol Ther 8:230-7. 2003
    ..These results indicate that therapeutic attempts to induce caspase-3 in malignant cells may prove useful in the treatment of bcl-x(L)-expressing tumors...
  32. ncbi request reprint Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients
    Obiageli N Onwuazor
    Blood 102:772-3. 2003
  33. ncbi request reprint Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance
    Jonathan B Pollett
    Division of Experimental Therapeutics, Toronto General Research Institute, and the Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    Blood 100:3819-21. 2002
    ..This finding has potential implications for the use of chemotherapy in t(4;14)-positive myeloma...
  34. ncbi request reprint A molecular compendium of genes expressed in multiple myeloma
    Jaime O Claudio
    Division of Experimental Therapeutics, Toronto General Research Institute, University Health Network, 610 University Avenue, Toronto, Ontario, M5G 2M9 Canada
    Blood 100:2175-86. 2002
    ..GenBank Accession numbers include BF169967-BF176369, BF185966-BF185969, and BF177280-BF177455...
  35. ncbi request reprint Insights from the gene expression profiling of multiple myeloma
    Jaime O Claudio
    Princess Margaret Hospital, 610 University Avenue, Room 5 126, Toronto, ON M5G 2M9, Canada
    Curr Hematol Rep 3:67-73. 2004
    ..These studies are providing insight into many previously unexplained features of this difficult disease...
  36. ncbi request reprint Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant
    A Keith Stewart
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 10:8170-6. 2004
    ....
  37. ncbi request reprint Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance
    Wilfrid Jaksic
    Department of Medical Oncology and Hematology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Canada
    J Clin Oncol 23:7069-73. 2005
    ..To determine whether primary drug resistance or rapid relapse explains the poor prognosis seen in t(4;14)-positive multiple myeloma (MM)...
  38. ncbi request reprint Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation
    Young Trieu
    Department of Medical Oncology Hematolog, Princess Margaret Hospital, University Health Network, Toronto, Ontario
    Mayo Clin Proc 80:1578-82. 2005
    ..To assess the efficacy and tolerability of weekly oral cyclophosphamide in combination with alternate-day prednisone (CP) as salvage therapy for patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (ASCT)...
  39. ncbi request reprint The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
    Suzanne Trudel
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, 620 University Avenue, Toronto, Ontario, Canada
    Clin Cancer Res 13:621-9. 2007
    ..The aim of this study is to investigate the antimyeloma activity of a novel Bcl-2 family inhibitor, ABT-737, in preclinical treatment of multiple myeloma...
  40. ncbi request reprint Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
    Hong Chang
    Department of Laboratory Hematology, Princess Margaret Hospital University Health Network, McLaughlin Center for Molecular Medicine, University of Toronto, ON, Canada
    Blood 106:353-5. 2005
    ..001), a shorter progression-free survival (median, 11.5 versus 25.8 months; P < .001), and a shorter overall survival (median, 19.2 versus 46.3 months; P < .001)...
  41. ncbi request reprint Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group
    Christine I Chen
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:1570-5. 2007
    ..To evaluate the efficacy and toxicity of single-agent bortezomib in Waldenström's macroglobulinemia (WM)...
  42. ncbi request reprint Antigenic open reading frames from HHV-8 are present in multiple myeloma patients and normal individuals at similar frequency
    Yuan Xiao Zhu
    Department of Medical Oncology, The Princess Margaret Hospital, Toronto General Hospital Research Institute, Ont, Canada
    Leuk Lymphoma 43:369-75. 2002
    ..HHV-8 infection appears to be common in the general population when sensitive PCR is employed and multiple samples are analyzed...
  43. ncbi request reprint Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial
    William F Clark
    University of Western Ontario, London, Ontario, Canada
    Ann Intern Med 143:777-84. 2005
    ..Two small, randomized trials provide conflicting evidence about the benefits of plasma exchange for patients with acute renal failure at the onset of multiple myeloma...
  44. ncbi request reprint Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma
    Suzanne Trudel
    Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    Blood 109:5430-8. 2007
    ..Taken together, these studies describe a novel BH3 mimic with selectivity for Mcl-1, and support the therapeutic application of GX015-070 for diverse neoplasias including multiple myeloma...
  45. ncbi request reprint Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma
    Jaime O Claudio
    Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Am J Pharmacogenomics 5:35-43. 2005
    ..The use of pharmacogenomic strategies in myeloma is thus already changing medical practice...
  46. ncbi request reprint A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer
    Suzane Trudel
    1Division of Hematology Oncology and Urology, The Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Cancer Gene Ther 10:755-63. 2003
    ..3%, range 17-69%). At higher doses, PSA values initially increased after injection, then fell to baseline prior to surgery. This trial demonstrates the feasibility and safety of intraprostatic adenovector-mediated IL-2 gene delivery...
  47. ncbi request reprint Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma
    Joshua L Paterson
    Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    Br J Haematol 124:595-603. 2004
    ..Myeloma cells lacking the t(4;14) or with the t(4;14) and a secondary RAS mutation did not respond to therapy. These findings support the development of clinical trials of early intervention with FGFR3 inhibitors in t(4;14) myeloma...
  48. ncbi request reprint Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo
    Young Trieu
    Division of Experimental Therapeutics, Toronto General Research Institute, McLaughlin Centre for Molecular Medicine, Toronto, Ontario, Canada
    Cancer Res 64:3271-5. 2004
    ..Our data demonstrate that AdsIL-13Ralpha2 can suppress HL growth in vitro and in vivo...
  49. ncbi request reprint The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
    Suzanne Trudel
    University Health Network, Princess Margaret Hospital, McLaughlin Centre of Molecular Medicine, 620 University Avenue, Rm 8204, Toronto, Ontario, Canada M5G 2C1
    Blood 107:4039-46. 2006
    ..The data demonstrate that PRO-001 is a potent and specific inhibitor of FGFR3 and deserves further study for the treatment of FGFR3-expressing myeloma...
  50. ncbi request reprint CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
    Suzanne Trudel
    Department of Medical Oncology, University Health Network, Princess Margaret Hospital and McLaughlin Centre of Molecular Medicine, University of Toronto, 620 University Ave, Rm 8 204, Toronto, ON, Canada M5G 2C1
    Blood 105:2941-8. 2005
    ..Finally, therapeutic efficacy of CHIR-258 was demonstrated in a xenograft mouse model of FGFR3 MM. These studies support the clinical evaluation of CHIR-258 in MM...
  51. doi request reprint Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
    Donna E Reece
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Suite 5 207, Toronto, Ontario, M5G 2M9 Canada
    J Clin Oncol 26:4777-83. 2008
    ....
  52. doi request reprint Cyproheptadine displays preclinical activity in myeloma and leukemia
    Xinliang Mao
    Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON, Canada
    Blood 112:760-9. 2008
    ..Because the drug is well tolerated and already approved in multiple countries for clinical use as an antihistamine and appetite stimulant, it could be moved directly into clinical trials for cancer...
  53. ncbi request reprint MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
    Esther Masih-Khan
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    Blood 108:3465-71. 2006
    ..Our observation is the first to directly link an initiating IgH translocation not only to MM-cell growth and survival but also to the disease-associated bone disease...

Research Grants7

  1. A Genome Wide RNAi Vulnerability Map for Myeloma
    ALEXANDER KEITH STEWART; Fiscal Year: 2010
    ..This genomic scale analysis and the creation of a vulnerability map of Myeloma, is a prerequisite to further our global understanding of this disease and how treatments may be both personalized and optimized. ..
  2. The Molecular Basis for Bortezomib Activity
    Alexander Stewart; Fiscal Year: 2007
    ..The ultimate goal of our entire study will be to generate new sensitizer drugs to be used in combination therapy to increase the clinical success rate of bortezomib or other PI therapy. ..
  3. The Molecular Basis for Bortezomib Activity
    Alexander Stewart; Fiscal Year: 2009
    ..The ultimate goal of our entire study will be to generate new sensitizer drugs to be used in combination therapy to increase the clinical success rate of bortezomib or other PI therapy. ..
  4. The Molecular Basis for Bortezomib Activity
    ALEXANDER KEITH STEWART; Fiscal Year: 2010
    ..The ultimate goal of our entire study will be to generate new sensitizer drugs to be used in combination therapy to increase the clinical success rate of bortezomib or other PI therapy. ..